New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
14:55 EDTALXNAlexion informed Health Ministers will not follow AGNSS Soliris recommendation
Alexion Pharma UK, a subsidiary of Alexion Pharmaceuticals, announced it has been informed by the National Specialised Commissioning Team that the Ministers of Health have decided to not follow a positive recommendation by the Advisory Group for National Specialised Services, or AGNSS, when assessing Soliris as a treatment for patients with atypical haemolytic uraemic syndrome. The Ministers of Health have overruled this expert committee recommendation and instead referred consideration of Soliris for the treatment of patients with aHUS to the National Institute for Health and Clinical Excellence. Alexion said it is committed to working with the Health Ministers to make Soliris available to children and adults as quickly as possible, and calls upon the Ministers to accept the recommendation of the significant number of experts and lay people called upon to review Soliris without delay, and to reverse his decision and accept the recommendation of AGNSS in the best interests of aHUS patients in England. Alexion said, "It is important to underscore that the UK Government developed a specific process and authorised a committee, AGNSS, to evaluate treatments addressing patients with very rare disorders, and that AGNSS concluded that 'eculizumab should be routinely nationally commissioned for patients with aHUS.'"
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:09 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
November 19, 2014
10:28 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
November 18, 2014
07:52 EDTALXNFDA Drug Safety & Risk Management Advisory Committee to hold a meeting
The Committee discusses the risk management of Alexion Pharmaceuticals' Eculizumab (Soliris) is a meeting being held at FDA Silver Spring, Maryland offices on November 18 at 9 am. Webcast Link
November 16, 2014
13:04 EDTALXNAlexion says data supports effectiveness of sustained Soliris treatment in aHUS
Subscribe for More Information
November 10, 2014
15:54 EDTALXNAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:20 EDTALXNJPMorgan biotech analyst to hold an analyst/industry conference call
U.S. SMid Biotech Analyst Rama, along with Key Opinion Leader Dr. Hickman Simmons from Vanderbilt University, discuss Alexion Pharmaceuticals' Asfotase Alfa and Hypophosophatasia on an Analyst/Industry conference call to be held on November 11 at 11 am.
06:31 EDTALXNAlexion announces planned retirement of co-founder, COO Stephen Squinto
Alexion announced the planned retirement of company co-founder Stephen Squinto, effective January 1, 2015. Squinto currently serves as Executive Vice President, Chief Global Operations Officer. He co-founded Alexion in 1992 with Leonard Bell, M.D., the Company’s principal founder and current Chairman and Chief Executive Officer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use